▼ This medicinal product is subject to additional monitoring.

This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Reporting forms and information can be found at www.medicinesauthority.gov.mt/adrportal. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (011707 367554. By reporting side effects you can help provide more

Emergency Contact Phone Numbers

Office Hours	
Out of Hours	

information on the safety of this medicine.



Marketing authorisation holder: Roche Registration Ltd, 6 Falcon Way, Shire Park,

Walkening automisation moited: Notice registration Ltd., or already says, sillier Faral, wellwyn Garden City, AL7 1TW, United Kingdom. Envedge is a registered trademark.

RXUKERIV00205a Date of preparation: November 2016

Erivedge[®] (vismodegib) Patient reminder card

This educational material is provided by Roche Products Limited and mandatory as a condition of the Marketing Authorisation in order to further minimise important selected risks

Erivedge may harm or cause the death of an unborn child.

FEMALE PATIENTS who are able to become pregnant must:

treatment and for 24 months after your last dose (please refer to the "Erivedge" Pregnancy Prevention Programme: Important information for men and women taking Erivedge about pregnancy prevention and contraception" for more information)

• always use **2 forms** of recommended contraception during

 have monthly pregnancy tests during treatment to monitor for pregnancy

MALE PATIENTS must:

- always use a condom (with spermicide, if available) when having sex with female partners during treatment and for 2 months from final dose
- not donate semen during treatment and for 2 months after the final dose

You must talk to your healthcare professional immediately if you or your sexual partner misses a period, suspect a pregnancy, or are pregnant.

- FEMALE PATIENTS: talk to your doctor if you suspect a pregnancy while taking Erivedge and for 24 months after your final dose.
- MALE PATIENTS: talk to your doctor if your female partner suspects that she is pregnant while you are taking Erivedge and for 2 months after your final dose.

ALL PATIENTS must:

- never give this medicine to anyone else
- not donate blood during treatment and for 24 months after the final dose
- return all unused capsules at the end of treatment